Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: Complex Regional Pain Syndromes
Interventions: Ketamine, Midazolam, Normal Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2099
U.S. locations: 1
States / cities: Stanford, California

Conditions: Postural Tachycardia Syndrome
Interventions: placebo sugar pill, Pyridostigmine Pill, Galantamine Pill, Vagal stimulation, Sham vagal stimulation; Drug · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy
Interventions: PF-02545920, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: New Haven, Connecticut

Conditions: Amyotrophic Lateral Sclerosis
Interventions: prosetin, placebo; Drug
Lead sponsor: ProJenX; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • San Antonio, Texas

Conditions: Measuring THC-induced Cognitive Impairment Using a Mobile Application
Interventions: Dronabinol, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 35 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Diseases
Interventions: YSPSL, placebo; Drug
Lead sponsor: Y's Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 11 more

Conditions: Lymphoma, Non-Hodgkin
Interventions: Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 10
States / cities: Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more

Conditions: Dengue
Interventions: TetraVax-DV-TV003, rDEN2∆30-7169, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Neurofibromatosis Type 1, Learning Disability, Reading Disability, NF1
Interventions: Lovastatin, reading tutoring intervention, Placebo Oral Tablet, Other Academic "sham" tutoring; Drug · Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 8 Years to 20 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Outcomes of Single Oral Dose
Interventions: DMAA; Dietary Supplement
Lead sponsor: University of Memphis; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Back Pain, Neck Pain
Interventions: Cannabis, Oxycodone, Placebo for Cannabis, Placebo for Oxycodone; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes Mellitus Type 2
Interventions: EGT0001442, Placebo capsules to match EGT0001442; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Birmingham, Alabama • National City, California • Denver, Colorado + 4 more

Conditions: Patent Ductus Arteriosus
Interventions: Early ibuprofen, Late ibuprofen expectant group (placebo); Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 1 Day to 14 Days
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Human Immunodeficiency Virus
Interventions: Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Crohn's Disease
Interventions: Placebo matching with BMS-945429, BMS-945429; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 8
States / cities: La Jolla, California • San Diego, California • Lone Tree, Colorado + 5 more

Conditions: Obesity Adult Onset
Interventions: Grape Seed Extract; Dietary Supplement
Lead sponsor: California Baptist University; Other
Eligibility: 18 Years to 29 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Riverside, California

Conditions: CBD, Neural Responses
Interventions: Cannabidiol, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Determine Effect of Vitamin D on Bone Health in Elderly African American Women
Interventions: Vitamin D 3, placebo; Dietary Supplement · Other
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 60 Years and older · Female only
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV MAT, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 49 Years · Female only
Enrollment: 384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more

Conditions: Anal Chlamydia Infection
Interventions: Azithromycin, Doxycycline, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Canakinumab 150 mg, Placebo to Canakinumab; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more

Conditions: Dyslipidemia, Healthy Volunteers
Interventions: TAP311; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Covid19
Interventions: VIR-7831 (sotrovimab), Placebo; Biological · Drug
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 63
States / cities: Anniston, Alabama • Cullman, Alabama • Mesa, Arizona + 49 more

Conditions: Septic Shock
Interventions: Hydroxocobalamin, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

Ketamine and Midazolam Infusions for CRPS: Feasibility Study

Vagal Stimulation in POTS

Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects

A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS

Developing a Mobile Method to Measure THC-induced Impairment

YSPSL for Prevention of Delayed Graft Function Part B

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults

Interventions for Reading Disabilities in NF1

Pharmacokinetic Effects of Oral DMAA

Cannabis Versus Oxycodone for Pain Relief

Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus

Timing of PDA Closure and Respiratory Outcome in Premature Infants

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

Effects of Chronic Dietary Grape Seed Extract Supplementation on Aortic Stiffness and Hemodynamic Responses to Exercise in Obese Males

Sex Differences in Neural Response to Cannabidiol

Vitamin D and Osteoporosis Prevention in Elderly African American Women

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

A Trial of Vitamin B12 in Septic Shock